drugset / Trial / NCT01262456
Investigation of the Superiority Effect of Orally Disintegrating Desmopressin Tablets to Placebo in Terms of Night Voids Reduction in Nocturia Adult Male Patients
RandomizedParallel-groupDouble-blindTreatment
Summary
The purpose of this trial was to confirm/establish long-term safety and efficacy of desmopressin orally disintegrating tablets at dose levels of 50 μg and 75 μg and to further evaluate the safety of an efficacious higher dose level of 100 μg in males with nocturia.
Timeline
- Start
- 2011-02
- Primary completion
- 2012-01
- Completion
- 2012-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Desmopressin | Peptide | 50 ug | Oral |
| Subject | Desmopressin | Peptide | 75 ug | Oral |
| Subject | Desmopressin | Peptide | 100 ug | Oral |
Indications
No indication recorded.